The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
KTE-X19 CAR T cell therapy in relapsed or refractory mantle-cell lymphoma
Open accessAbstract
BACKGROUND: Patients with relapsed or refractory mantle-cell lymphoma who have disease progression during or after the receipt of Bruton's tyrosine kinase (BTK) inhibitor therapy have a poor prognosis. KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, may have benefit in patients with relapsed or refractory mantle-cell lymphoma. METHODS: CAR T cells per kilogram of body weight. The primary end point was the percentage of patients with an objective response (complete or partial response) as assessed by an independent radiologic review committee according to the Lugano classification. Per the protocol, the primary efficacy analysis was to be conducted after 60 patients had been treated and followed for 7 months. RESULTS: A total of 74 patients were enrolled. KTE-X19 was manufactured for 71 patients and administered to 68. The primary efficacy analysis showed that 93% (95% confidence interval [CI], 84 to 98) of the 60 patients in the primary efficacy analysis had an objective response; 67% (95% CI, 53 to 78) had a complete response. In an intention-to-treat analysis involving all 74 patients, 85% had an objective response; 59% had a complete response. At a median follow-up of 12.3 months (range, 7.0 to 32.3), 57% of the 60 patients in the primary efficacy analysis were in remission. At 12 months, the estimated progression-free survival and overall survival were 61% and 83%, respectively. Common adverse events of grade 3 or higher were cytopenias (in 94% of the patients) and infections (in 32%). Grade 3 or higher cytokine release syndrome and neurologic events occurred in 15% and 31% of patients, respectively; none were fatal. Two grade 5 infectious adverse events occurred. CONCLUSIONS: KTE-X19 induced durable remissions in a majority of patients with relapsed or refractory mantle-cell lymphoma. The therapy led to serious and life-threatening toxic effects that were consistent with those reported with other CAR T-cell therapies. (Funded by Kite, a Gilead company; ZUMA-2 ClinicalTrials.gov number, NCT02601313.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These CAR T-cells were able to elicit complete responses (CR) in 32-67% of lymphoma patients and showed better CR rates in patients with leukemia (16-19).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [18]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“First, most CAR T cell trials to date have used autologous peripheral blood and apheresis as the main cell sources for manufacturing (9-18,21,22).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Self-citationCheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Revised response criteria for malignant lymphoma.
Cheson, B. D., Pfistner, B., Juweid, M., Gascoyne, R., Specht, L., Horning, S., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,537
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Self-citationInterval Estimation for a Binomial Proportion
Brown, L. D., Cai, T., & Dasgupta, A. (2001) · Statistical Science · doi:10.1214/ss/1009213286 · Cited by 3,746
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
A note on quantifying follow-up in studies of failure time
SCHEMPER, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,592
Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30864-7 · Cited by 2,286
Self-citationTargeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
Self-citation2016 US lymphoid malignancy statistics by World Health Organization subtypes
Teras, L. R., DeSantis, C. E., Cerhan, J. R., Morton, L. M., Jemal, A., & Flowers, C. R. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21357 · Cited by 1,125
Flagged first, then by citations
Cited by
Sorted by citations
Items 901–1,000 of 1,001
Salles, G., Chen, J. M. H., Zhang, I., Kerbauy, F. R., Wu, J. J., Wade, S. W., Nunes, A., Feng, C., Kloos, I., Peng, W., et al. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02822-z · Cited by 9
Self-citationBorogovac, A., & Siddiqi, T. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2023.100 · Cited by 12
Infections in patients with mantle cell lymphoma
Abalo, K., Ekberg, S., Andersson, T., Pahnke, S., Albertsson‐Lindblad, A., Smedby, K. E. E., Jerkeman, M., & Glimelius, I. C. (2024) · HemaSphere · doi:10.1002/hem3.121 · Cited by 9
Bakhtiyaridovvombaygi, M., Yazdanparast, S., Kheyrandish, S., Safdari, S. M., Samani, F. A., Sohani, M., Jaafarian, A. S., Damirchiloo, F., Izadpanah, A., Parkhideh, S., et al. (2024) · Biomarker Research · doi:10.1186/s40364-024-00610-z · Cited by 9
Delivery Systems Developed for Treatment Combinations to Improve Adoptive Cell Therapy
Xu, F., Ni, Q., Gong, N., Xia, B., Zhang, J., Guo, W., Hu, Z., Li, J., & Liang, X. (2024) · Advanced Materials · doi:10.1002/adma.202407525 · Cited by 11
Wan, H., Weng, S., Sheng, S.-M., Kuang, Z., Wang, Q., & Hu, L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1435127 · Cited by 9
Grégoire, C., de Oliveira, B. C., Caimi, P. F., Caers, J., & Melenhorst, J. J. (2024) · British Journal of Haematology · doi:10.1111/bjh.19751 · Cited by 12
Ma, J., Yan, J., Liu, M., Yan, C., Tang, X., Qiu, H., Miao, M., Han, Y., Li, L., Kang, L., et al. (2024) · HemaSphere · doi:10.1002/hem3.70007 · Cited by 11
Self-citationEvolving strategies to overcome barriers in CAR-T cell therapy for acute myeloid leukemia
Colonne, C. K., Kimble, E. L., & Turtle, C. J. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2420614 · Cited by 10
Kopmar, N. E., & Cassaday, R. D. (2024) · Cancer Management and Research · doi:10.2147/cmar.s379807 · Cited by 11
Bindal, P., Trottier, C. A., Elavalakanar, P., Dodge, L. E., Kim, S., Logan, E., Ma, S., Liegel, J. J., Arnason, J. E., & Alonso, C. D. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2439513 · Cited by 9
Avolio, E., Bassani, B., Campanile, M., Mohammed, K. A. K., Muti, P. C., Bruno, A., Spinetti, G., & Madeddu, P. R. (2024) · Pharmacological Reviews · doi:10.1016/j.pharmr.2024.100033 · Cited by 9
Lei, Q., Deng, H., & Sun, S. (2025) · Life Medicine · doi:10.1093/lifemedi/lnaf002 · Cited by 9
Liebers, N., Boumendil, A., Finel, H., Edelmann, D., Kobbe, G., Baermann, B., Serroukh, Y. I. M., Blaise, D., Beelen, D. W., Solano, C., et al. (2025) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-24-0178 · Cited by 9
Emapalumab for severe cytokine release syndrome in solid tumor CAR-T: a case report
Ruemmele, T., Macedo, R., Stein, M. N., Chan, H. T., Mapara, M. Y., Jacquemont, C. F., & Reshef, R. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1543622 · Cited by 9
Advances and challenges in cancer immunotherapy: Strategies for personalized treatment
Azmal, M., Miah, M. M., Prima, F. S., Paul, J. K., Haque, A. S. N. B., & Ghosh, A. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152345 · Cited by 12
Naik, S., Aplenc, R., Baumeister, S. H. C., Becilli, M., Bhagwat, A. S., Bonifant, C. L., Budde, L. E., Chien, C. D., Curran, K. J., Daniyan, A. F., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025017011 · Cited by 9
Fathah, D. E., & Ejaz, S. (2025) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-025-00317-8 · Cited by 9
Cole, E. B., Lamcaj, S., Sydenstricker, A. V., Voss, A., Hiner, C. R., Hur, H. B., Kandpal, M., Pena, N. V., Zheng, J. H., Xiong, Y., et al. (2026) · Science Advances · doi:10.1126/sciadv.aec2632 · Cited by 9
Immunotherapies in Non-Hodgkin’s Lymphoma
Bezombes, C., & Pérez‐Galán, P. (2021) · Cancers · doi:10.3390/cancers13143625 · Cited by 9
Frosch, Z. A. K., Namoglu, E. C., Mitra, N., Landsburg, D. J., Nasta, S. D., Bekelman, J. E., Iyengar, R., Guerra, C. E., & Schapira, M. M. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00312 · Cited by 9
Chimeric antigen receptor T-cell therapy in adult patients with B-cell lymphoproliferative diseases
Gavrilina, O. A., Galstyan, G. M., Shchekina, A. E., Сергеевна, К. Е., Maschan, M. A., Troitskaya, V. V., Koroleva, D. A., Zvonkov, E. E., Таймуразовна, Ф. З., Vasilieva, V. A., et al. (2022) · Гематология и трансфузиология · doi:10.35754/0234-5730-2022-67-1-8-28 · Cited by 9
Hao, Y., Chen, P., Yuan, X., Zhao, A., Liang, Y., Liu, H., & Qian, W. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i19.6555 · Cited by 9
Guarini, A. R., Radice, G., Peragine, N., Buracchi, C., Propris, M. S. D., Rocco, A. D., Rocco, A. D., Chiaretti, S., Moretti, A., Napolitano, S., et al. (2023) · Cancers · doi:10.3390/cancers15092411 · Cited by 9
Vinke, P. C., Combalia, M., de Bock, G. H., Leyrat, C., Spanjaart, A. M., Dalle, S., da Silva, M. G., Essongue, A., Rabier, A., Pannard, M., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-069090 · Cited by 9
Self-citationConci, S., Catalano, G., Roman, D., Zecchetto, C., Lucin, E., Bellis, M. D., Tripepi, M., Guglielmi, A., Milella, M., & Ruzzenente, A. (2023) · International Journal of Medical Sciences · doi:10.7150/ijms.82008 · Cited by 9
Harnessing the Gut Microbiota to Potentiate the Efficacy of CAR T Cell Therapy
Gabrielli, G., Shouval, R., Ghilardi, G., van den Brink, M. R. M., & Ruella, M. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000950 · Cited by 10
CAR-T Cell Therapy in the Treatment of Pediatric Non-Hodgkin Lymphoma
Ostojska, M., Nowak, E., Twardowska, J., Lejman, M., & Zawitkowska, J. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13111595 · Cited by 10
Bock, A. M., Gile, J. J., Larson, M. C., Poonsombudlert, K., Tawfiq, R. K., Maliske, S. M., Maurer, M. J., Kabat, B., Paludo, J., Inwards, D. J., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00942-3 · Cited by 10
Genome editing approaches for universal chimeric antigen receptor T cells
Mishra, A. K., & Qasim, W. (2024) · EJC Paediatric Oncology · doi:10.1016/j.ejcped.2024.100149 · Cited by 9
Charting new paradigms for CAR-T cell therapy beyond current Achilles heels
Li, Y., Hu, Z., Li, Y., & Wu, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1409021 · Cited by 10
Evaluation and management of chimeric antigen receptor (CAR) T-cell-associated neurotoxicity
Castro, L. N. G., & Dietrich, J. (2020) · Neuro-Oncology Practice · doi:10.1093/nop/npaa080 · Cited by 9
Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies
Al-Juhaishi, T. M. S., & Ahmed, S. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00615-7 · Cited by 9
Yuan, J., Zhang, Q., Wu, S., Yan, S., Zhao, R., Sun, Y., Tian, X., & Zhou, K. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s283486 · Cited by 9
Khurana, A., Dalland, J., Young, J. R., Inwards, D. J., & Paludo, J. (2021) · American Journal of Hematology · doi:10.1002/ajh.26233 · Cited by 9
Advances in immune therapies in hematological malignancies
Mazzarella, L., Enblad, G., Olweus, J., Malmberg, K., & Jerkeman, M. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13395 · Cited by 9
Disease-specific outcomes after chimeric antigen receptor T-cell therapy
Lemoine, J., Vic, S., & Houot, R. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.10.022 · Cited by 9
Self-citationIn vivo experimental mouse model to test CD19CAR T cells generated with different methods
Fåne, A., Myhre, M. R., Inderberg, E. M., & Wälchli, S. (2022) · Methods in cell biology · doi:10.1016/bs.mcb.2021.11.001 · Cited by 9
Lau, S. P., Land, F. R. V. ‘., van der Burg, S. H., Homs, M. Y. V., Lolkema, M. P., Aerts, J. G. J. V., & van Eijck, C. H. J. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-060431 · Cited by 9
Ring, A., Grob, B., Aerts, E., Ritter, K., Volbracht, J., Schär, B., Greiling, M., & Müller, A. M. S. (2022) · Annals of Hematology · doi:10.1007/s00277-022-04881-0 · Cited by 9
Mekkaoui, L., Tejerizo, J. G., Abreu, S., Rubat, L., Nikoniuk, A., Macmorland, W., Horlock, C., Matsumoto, S., Williams, S., Smith, K., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.12.006 · Cited by 9
CAR-T cell Therapies for B-cell Lymphoid Malignancies
Vanegas, Y. A. M., Mohty, R., Gadd, M. E., Luo, Y., Aljurf, M. D., Qin, H., & Kharfan‐Dabaja, M. A. (2022) · Hematology/Oncology and Stem Cell Therapy · doi:10.56875/2589-0646.1026 · Cited by 11
RETRACTED ARTICLE: Molecular and therapeutic effect of CRISPR in treating cancer
Rodrigo, S., Senasinghe, K., & Quazi, S. (2023) · Medical Oncology · doi:10.1007/s12032-022-01930-6 · Cited by 10
RetractedCellular Therapies for Mantle Cell Lymphoma
Yassine, F., Sandoval-Sus, J. D., Ayala, E., Chávez, J. C., Hamadani, M., & Kharfan‐Dabaja, M. A. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.01.026 · Cited by 9
CAR T-Cell therapies in lymphoma: current landscape, ongoing investigations, and future directions
Haydu, J. E., & Abramson, J. S. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.39 · Cited by 9
Gaffney, K. J., Davis, J. A., McGann, M., Edwards, K. H., Ahmed, Z., Butcher, C., Greenwell, B., Hess, B. T., & Hashmi, H. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231170757 · Cited by 8
Gupta, S., Kohorst, M. A., & Alkhateeb, H. B. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14132 · Cited by 8
A Review of Practice-Changing Therapies in Oncology in the Era of Personalized Medicine
Capella, M. P., & Esfahani, K. (2024) · Current Oncology · doi:10.3390/curroncol31040143 · Cited by 8
Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy
Teo, P. Y., Jung, Y., Quach, D. H., Koh, J., Ong, R., Goh, A. X., Tan, A. S. M., Ng, C. H., Seh, C. C., Tan, K. W., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-1001 · Cited by 8
Al‐Ibraheem, A., Abdlkadir, A. S., Al-Adhami, D. A., Sathekge, M. M., Bom, H. H.-S., Ma’koseh, M., Mansour, A. H., Abdel‐Razeq, H., Al-Rabi, K. H., Estrada-Lobato, E., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1424269 · Cited by 8
Xu, Y., Zhang, X., Xin, D., Zhang, J., Wang, L., Fan, Y., Chen, B., Lei, W., Qiu, X., Jiang, H., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0051 · Cited by 8
Park, H., Jeong, H., Yim, H. W., & Kim, N. J. (2024) · Scientific Reports · doi:10.1038/s41598-024-77210-2 · Cited by 12
Mao, D., Reiner, A. S., Chen, X., Park, J. H., Pennisi, M., Perales, M., Avila, E. K., & Santomasso, B. (2024) · Scientific Reports · doi:10.1038/s41598-024-80566-0 · Cited by 8
Cellular therapies in rheumatic and musculoskeletal diseases
Franco-Fuquen, P., Figueroa-Aguirre, J., Martínez, D. A., Moreno-Cortes, E. F., García-Robledo, J. E., Vargas-Cely, F. S., Castro-Martinez, D. A., Al‐Maini, M., & Castro, J. E. (2024) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2024.100264 · Cited by 9
Unmet needs and lived experience of patients receiving CAR T-cell therapy
O'Shea, P., Johnson, P. C., El-Jawahri, A., & Leblanc, T. W. (2025) · Leukemia and Lymphoma · doi:10.1080/10428194.2025.2455488 · Cited by 8
Chimeric antigen receptor therapies: Development, design, and implementation
Lee, M. J., Cichocki, F. M., & Miller, J. S. (2025) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2025.04.005 · Cited by 8
Dreger, P., Ahmed, S., Bazarbachi, A. A., Dietrich, S., Fenske, T. S., Ghosh, N., Hermine, O., & Hamadani, M. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02599-x · Cited by 8
Premchandani, T., Qutub, M., Tatode, A., Umekar, M. J., Taksande, J., Hussain, U., & Khidkikar, S. R. (2025) · Immunologic Research · doi:10.1007/s12026-025-09687-6 · Cited by 9
CAR NK cell therapy for solid tumors: potential and challenges
Yu, Y., & Ho, M. (2025) · Antibody Therapeutics · doi:10.1093/abt/tbaf019 · Cited by 11
Nguyen, D. A. H., & Quang, M. T. (2025) · Molecular Biotechnology · doi:10.1007/s12033-025-01533-2 · Cited by 12
Clinical progress of engineered cellular immunotherapies for autoimmunity
Solimani, F., Amagai, M., Bollard, C. M., & Payne, A. S. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03001-x · Cited by 8
Cardiotoxicity of T cell immunotherapies
Raddatz, M. A., Stein-Merlob, A. F., Mahmood, S. S., Ganatra, S., Addison, D., Lin, T. L., Larson, S. M., & Yang, E. H. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01265-z · Cited by 9
de Folmont, A. D. T., Bourhis, J.-H., Chouaı̈b, S., & Terry, S. (2021) · Immuno · doi:10.3390/immuno1030010 · Cited by 9
Heard, A. D., Chang, J., Warrington, J. M., & Singh, N. (2021) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2021.101304 · Cited by 8
Johnson, P. C., Jacobson, C. A., Yi, A., Gaballa, M., Horick, N., Rabideau, D. J., Lindell, K., Depinho, G. D., El-Jawahri, A. R., & Frigault, M. J. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004567 · Cited by 8
Self-citationManagement of CAR T-cell Related Toxicities
Murthy, H. S., Yassine, F., Iqbal, M., Alotaibi, S., Moustafa, M. A., & Kharfan‐Dabaja, M. A. (2022) · Hematology/Oncology and Stem Cell Therapy · doi:10.56875/2589-0646.1029 · Cited by 8
Regulatory Measures to Improve the Safety of CAR-T-Cell Treatment
Berg, P., Schönefeld, S., Ruppert‐Seipp, G., & Funk, M. B. (2022) · Transfusion Medicine and Hemotherapy · doi:10.1159/000526786 · Cited by 8
Evaluating the Patient with Neurotoxicity after Chimeric Antigen Receptor T-cell Therapy
Ensign, S. P. F., Gaulin, C., Hrachova, M., Ruff, M. W., Harahsheh, E. Y., Vicenti, K., Castro, J. E., Munoz, J. L., Rosenthal, A. C., & Mrugała, M. M. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-01035-2 · Cited by 8
Self-citationMiyao, K., Yokota, H., & Sakemura, R. L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1082235 · Cited by 8
The Role of mTOR in B Cell Lymphoid Malignancies: Biologic and Therapeutic Aspects
Karatrasoglou, E. A., Dimou, M., Piperidou, A., Lakiotaki, E., Korkolopoulou, P. A., & Vassilakopoulos, T. P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814110 · Cited by 8
Targeting EBV‐encoded products: Implications for drug development in EBV‐associated diseases
Lv, M., Ding, Y., Zhang, Y., & Liu, S. (2023) · Reviews in Medical Virology · doi:10.1002/rmv.2487 · Cited by 8
Prophylactic use of interleukin 6 monoclonal antibody can reduce CRS response of CAR-T cell therapy
Dou, B.-T., Ren, S.-H., Qiu, L., Zhang, X., Zhang, N., Cai, J., Chen, D., Zhang, Q., Yao, H., & Fan, F. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2023.1265835 · Cited by 8
Nylund, P., Nikkarinen, A., Ek, S., & Glimelius, I. C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1373269 · Cited by 8
Herbaux, C., Bret, C., Bachy, E., Bories, P., Blasi, R. D., Cuffel, A., Gastinne, T., Lamy, T., Roussel, M., Bouabdallah, K. K., et al. (2024) · Haematologica · doi:10.3324/haematol.2023.284786 · Cited by 8
Self-citationCAR T-cell therapy in cancer: Integrating nursing perspectives for enhanced patient care
Gupta, A., Dagar, G., Rehmani, M. U., Prasad, C. P., Saini, D., Singh, M. K., & Shankar, A. (2024) · Asia-Pacific Journal of Oncology Nursing · doi:10.1016/j.apjon.2024.100579 · Cited by 13
Stella, F., Chiappella, A., Magni, M., Bonifazi, F., Philippis, C. D., Musso, M., Cutini, I., Ljevar, S., Barbui, A. M., Farina, M., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19961 · Cited by 7
Kambhampati, S., Fakhri, B., Ai, W. Z., Kaplan, L. D., Tuscano, J. M., Wieduwilt, M. J., Sudhindra, A., Cavallone, E., Reiner, J., Aoun, C., et al. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.12.020 · Cited by 8
Chimeric Antigen Receptor T Cells for B-Cell Lymphoma
Newcomb, R. A., & Jacobson, C. A. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000509 · Cited by 8
Self-citationNovel Treatments for Mantle Cell Lymphoma: From Targeted Therapies to CAR T Cells
Wallace, D. S., & Reagan, P. M. (2021) · Drugs · doi:10.1007/s40265-021-01497-y · Cited by 8
Self-citationTaromi, S., Firat, E., Simonis, A., Braun, L. M., Apostolova, P., Elze, M., Passlick, B., Schumacher, A., Lagies, S., Frey, A., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.08.012 · Cited by 8
RetractedMathys, A., Bacher, U., Banz, Y., Legros, M., Taleghani, B. M., Novak, U., & Pabst, T. (2021) · Hematological Oncology · doi:10.1002/hon.2952 · Cited by 8
Immunotherapeutic Strategies in Cancer and Atherosclerosis—Two Sides of the Same Coin
Nettersheim, F. S., Picard, F. S. R., Hoyer, F. F., & Winkels, H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.812702 · Cited by 9
Sakemura, R. L., Cox, M. J., Bansal, A., Roman, C. M., Hefazi, M., Vernon, C. J., Glynn, D. L., Pandey, M. K., DeGrado, T. R., Siegler, E. L., et al. (2022) · Journal of Visualized Experiments · doi:10.3791/62334 · Cited by 8
Stolz, S. M., Roncador, M., Rösler, W., Zenz, T., Manz, M. G., Müller, A. M. S., & Widmer, C. C. (2022) · Swiss Medical Weekly · doi:10.4414/smw.2022.w30186 · Cited by 8
Socioeconomic and Racial Disparity in Chimeric antigen receptor T cell (CART)Therapy Access
Blue, B. J. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.06.004 · Cited by 8
Clinical trials for chimeric antigen receptor T-cell therapy: lessons learned and future directions
Schroeder, B., Jess, J., Sankaran, H., & Shah, N. N. (2022) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000723 · Cited by 8
Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis
Reinhardt, B., Lee, P. C., & Sasine, J. P. (2023) · Cells · doi:10.3390/cells12040531 · Cited by 9
Radhakrishnan, V. S., Lokireddy, P., Parihar, M., Prakash, P. S., & Menon, H. (2021) · Cancer Reports · doi:10.1002/cnr2.1590 · Cited by 8
CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies
Mi, J., Xu, J., Zhou, J., Zhao, W., Zhu, C. H., Melenhorst, J. J., & Chen, S. (2021) · Frontiers of Medicine · doi:10.1007/s11684-021-0904-z · Cited by 8
Psychopathologie et migration : repérage historique et épistémologique dans le contexte français
Gouriou, F. (2008) · HAL · Cited by 8
Wiedemann, G., Bacher, U., Joncourt, R., Solly, F., Widmer, C. C., Zeerleder, S. S., Novak, U., Pabst, T., & Porret, N. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168556 · Cited by 8
Chartier, M., Filosto, S., Peyret, T., Chiney, M. S., Milletti, F., Budka, J. A., Ndi, A., Dong, J., Vardhanabhuti, S., Mao, D., et al. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01413-z · Cited by 7
Antibody-Based Therapies for Peripheral T-Cell Lymphoma
Shafagati, N., Paul, S., Rozati, S., & Sterling, C. H. (2024) · Cancers · doi:10.3390/cancers16203489 · Cited by 7
Angelillo, P., Tomás, A. A., Campodonico, E., Novak, U., Gabellier, L., Blau, I. W., Kwon, M. J., Ram, R., Forcade, É., Besley, C., et al. (2024) · Bone Marrow Transplantation · doi:10.1038/s41409-024-02451-8 · Cited by 7
CAR-T Cells for the Treatment of Central Nervous System Tumours: Known and Emerging Neurotoxicities
Palazzo, L., Pieri, V., Berzero, G., & Filippi, M. (2024) · Brain Sciences · doi:10.3390/brainsci14121220 · Cited by 7
CD19-directed chimeric antigen receptor T-cell therapy: what can we learn from the haematologist?
Kuipers, M. T., & Kersten, M. J. (2025) · Lupus Science & Medicine · doi:10.1136/lupus-2024-001157 · Cited by 7
Self-citationChimeric antigen receptor-macrophages: Emerging next-generation cell therapy for brain cancer
Koppers, M. J. A., Monnikhof, M., Meeldijk, J., Koorman, T., & Bovenschen, N. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf059 · Cited by 7
Scalable and ultrafast CAR-T cell production using microfluidics
Витальевич, М. В., Arabuli, K. V., Николаевич, Г. И., Sergeev, V. S., Shakirova, A. I., Lepik, K. V., Kulagin, A., & Zyuzin, M. V. (2025) · Lab on a Chip · doi:10.1039/d5lc00139k · Cited by 7
Recent Advances in Molecular Research and Treatment for Melanoma in Asian Populations
Kado, S., & Komine, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115370 · Cited by 7
Epigenetic reprogramming holds promise in enhancing anti-tumor efficacy of CAR T cell therapy
Zheng, Y., Zhu, Q., Li, X., Ge, T., Wang, S., Jia, R., Yang, L., Wang, Y., & Zhuang, A. (2025) · Biotechnology Advances · doi:10.1016/j.biotechadv.2025.108649 · Cited by 7
Metadata
- Authors
- Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W., McSweeney, P. A., Miklos, D. B., Pagel, J. M., Kersten, M.-J., Milpied, N., Fung, H., Topp, M. S., Houot, R., Beitinjaneh, A., Peng, W., Zheng, L., Rossi, J. M., Jain, R. K., Rao, A. V., & Reagan, P. M.
- Affiliations
- Cleveland Clinic (US)
- From the University of Texas M.D. Anderson Cancer Center, Houston (M.W.), and Texas Oncology, Dallas (H.H.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (J.M.); John Theurer Cancer Center, Hackensack, NJ (A.G.); Moffitt Cancer Center, Tampa (F.L.L.), and the University of Miami, Miami (A.B.) — both in Florida; Dana–Farber Cancer Institute, Boston (C.A.J.); Cleveland Clinic Foundation, Cleveland (B.T.H.), and the Ohio State University Comprehensive Cancer Center, Columbus (S.J.); David Geffen...
- Fox Chase Cancer Center (US)
- Corresponding author
- Wang, Michael
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-04-02
- Volume
- 382
- Issue
- 14
- Pages
- 1331-1342
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7731441
- OpenAlex
- W3014583893
- Cited by
- 1,862
- References
- 30
- Citations by year
- 2026: 203 · 2025: 249 · 2024: 314 · 2023: 321 · 2022: 366 · 2021: 321 · 2020: 81
- FWCI
- 98.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Funders
- Kite, a Gilead Company
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tisagenlecleucel, CD19 CAR T-cell therapy, BTK inhibitor resistance, objective response, complete response, progression-free survival, overall survival, cytokine release syndrome, neurological adverse events, cytopenia
- MeSH terms
- Receptors, Chimeric Antigen, Adult, Aged, Antineoplastic Agents, Combined Modality Therapy, Humans, Infusions, Intravenous, Leukapheresis, Middle Aged, Recurrence, T-Lymphocytes, Vidarabine, Survival Analysis, Immunotherapy, Adoptive, Antigens, CD19, Lymphoma, Mantle-Cell
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
